Outcome measures in inflammatory rheumatic diseases

被引：42

作者：

Fransen, Jaap ^{[1
]}

van Riel, Piet L. C. M. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Rheumatol, NL-6500 HB Nijmegen, Netherlands

来源：

ARTHRITIS RESEARCH & THERAPY | 2009年 / 11卷 / 05期

关键词：

COLLEGE-OF-RHEUMATOLOGY; CLINICAL-TRIALS; ACTIVITY INDEX; ANKYLOSING-SPONDYLITIS; PRELIMINARY DEFINITION; IMPROVEMENT CRITERIA; ARTHRITIS; PROGRESSION; VALIDATION; REMISSION;

D O I：

10.1186/ar2745

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Inflammatory rheumatic diseases are generally multifaceted disorders and, therefore, measurement of multiple outcomes is relevant to most of these diseases. Developments in outcome measures in the rheumatic diseases are promoted by the development of successful treatments. Outcome measurement will increasingly deal with measurement of low levels of disease activity and avoidance of disease consequences. It is an advantage for patient management and knowledge transfer if the same outcomes are used in practice and in trials. Continuous measures of change are generally the most powerful and, therefore, are preferred as primary outcomes in trials. For daily clinical practice, outcome measures should reflect the patients' state and have to be easily derivable. The objective of this review is to describe recent developments in outcome measures for inflammatory rheumatic diseases for trials and clinical practice, with an emphasis on rheumatoid arthritis.

引用

页数：10

共 51 条

[1]

Reporting Disease Activity in Clinical Trials of Patients With Rheumatoid Arthritis: EULAR/ACR Collaborative Recommendations [J].

Aletaha, D. ;

Landewe, R. ;

Karonitsch, T. ;

Bathon, J. ;

Boers, M. ;

Bombardier, C. ;

Bombardieri, S. ;

Choi, H. ;

Combe, B. ;

Dougados, M. ;

Emery, P. ;

Gomez-Reino, J. ;

Keystone, E. ;

Koch, G. ;

Kvien, T. K. ;

Martin-Mola, E. ;

Matucci-Cerinic, M. ;

Michaud, K. ;

O'Dell, J. ;

Paulus, H. ;

Pincus, T. ;

Richards, P. ;

Simon, L. ;

Siegel, J. ;

Smolen, J. S. ;

Sokka, T. ;

Strand, V. ;

Tugwell, P. ;

van der Heijde, D. ;

van Riel, P. ;

Vlad, S. ;

van Vollenhoven, R. ;

Ward, M. ;

Weinblatt, M. ;

Wells, G. ;

White, B. ;

Wolfe, F. ;

Zhang, B. ;

Zink, A. ;

Felson, D. .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (10) :1371-1377

[2]

Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100

[3]

Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO

[4]

2-F

[5]

BOERS M, 1993, J RHEUMATOL, V20, P568

[6]

Making an impact on mortality in rheumatoid arthritis [J].

Boers, M ;

Dijkmans, B ;

Gabriel, S ;

Maradit-Kremers, H ;

O'Dell, J ;

Pincus, T .

ARTHRITIS AND RHEUMATISM, 2004, 50 (06) :1734-1739

[7]

DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].

BOMBARDIER, C ;

GLADMAN, DD ;

UROWITZ, MB ;

CARON, D ;

CHANG, CH .

ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640

[8]

Bruce B, 2005, CLIN EXP RHEUMATOL, V23, pS14

[9]

Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change [J].

Bruynesteyn, K ;

Boers, M ;

Kostense, P ;

van der Linden, S ;

van der Heijde, D .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :179-182

[10]

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis - A Department of Veterans Affairs cooperative study [J].

Clegg, DO ;

Reda, DJ ;

Mejias, E ;

Cannon, GW ;

Weisman, MH ;

Taylor, T ;

BudimanMak, E ;

Blackburn, WD ;

Vasey, FB ;

Mahowald, ML ;

Cush, JJ ;

Schumacher, HR ;

Silverman, SL ;

Alepa, FP ;

Luggen, ME ;

Cohen, MR ;

Makkena, R ;

Haakenson, CM ;

Ward, RH ;

Manaster, BJ ;

Anderson, RJ ;

Ward, JR ;

Henderson, WG .

ARTHRITIS AND RHEUMATISM, 1996, 39 (12) :2013-2020

← 1 2 3 4 5 6 →